- Home
- KPRX vs PETZ Comparison
KPRX vs PETZ Comparison
Compare KPRX & PETZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- PETZ
- Stock Information
- Founded
- KPRX 1998
- PETZ 2002
- Country
- KPRX United States
- PETZ China
- Employees
- KPRX N/A
- PETZ N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PETZ Steel/Iron Ore
- Sector
- KPRX Health Care
- PETZ Industrials
- Exchange
- KPRX Nasdaq
- PETZ Nasdaq
- Market Cap
- KPRX 9.2M
- PETZ 10.9M
- IPO Year
- KPRX N/A
- PETZ 2017
- Fundamental
- Price
- KPRX $2.15
- PETZ $1.01
- Analyst Decision
- KPRX Strong Buy
- PETZ
- Analyst Count
- KPRX 1
- PETZ 0
- Target Price
- KPRX $10.00
- PETZ N/A
- AVG Volume (30 Days)
- KPRX 53.1K
- PETZ 7.2K
- Earning Date
- KPRX 11-07-2025
- PETZ 11-13-2025
- Dividend Yield
- KPRX N/A
- PETZ N/A
- EPS Growth
- KPRX N/A
- PETZ N/A
- EPS
- KPRX N/A
- PETZ 0.27
- Revenue
- KPRX N/A
- PETZ $1,046,006.00
- Revenue This Year
- KPRX N/A
- PETZ N/A
- Revenue Next Year
- KPRX N/A
- PETZ N/A
- P/E Ratio
- KPRX N/A
- PETZ $6.10
- Revenue Growth
- KPRX N/A
- PETZ N/A
- 52 Week Low
- KPRX $2.05
- PETZ $0.65
- 52 Week High
- KPRX $4.18
- PETZ $1.68
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- PETZ 43.58
- Support Level
- KPRX $2.26
- PETZ $1.00
- Resistance Level
- KPRX $2.39
- PETZ $1.06
- Average True Range (ATR)
- KPRX 0.14
- PETZ 0.04
- MACD
- KPRX -0.02
- PETZ -0.00
- Stochastic Oscillator
- KPRX 16.03
- PETZ 7.41
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.